D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

4D Molecular Therapeutics (NASDAQ:FDMT) stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

These are known as capital allocation programs. 4D Molecular Therapeutics (NASDAQ:FDMT) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search ...

4D Molecular Therapeutics Inc. Annual stock financials by MarketWatch. View the latest FDMT financial statements, income statements and financial ratios.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MSC Industrial Direct Co Inc (Symbol: MSM), where a total of 4,676 contracts have traded so ...

Shares of 4D Molecular Therapeutics (FDMT) stock surged 80% in today’s session. This surge follows news of positive clinical trial data for the company’s key eye disease treatment. 4D Molecular is now ...

4D Molecular Therapeutics, Inc. (FDMT) has been beaten down lately with too much selling pressure. While the stock has lost 26% over the past four weeks, there is light at the end of the tunnel as it ...